Br J Psychiatry. 2008 May 1; 192:338-343 Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study Oberlander TF, Warburton W, Misri S, Aghajanian J. Human Early Learning Partnership, University of British Columbia, Vancouver, British Columbia, Canada Background: Late-gestational serotonin reuptake inhibitor (SRI) exposure has been linked to adverse neonatal outcomes; however, the impact of timing and duration of exposure is unknown. Aims: To determine whether late-gestational exposure to an SRI is associated with increased risk of adverse neonatal outcome relative to early exposure. Method: Population-based maternal and neonatal health records were linked to prenatal maternal prescription records for an SRI medication
J Am Geriatr Soc. 2006 Oct;54(10):1508-15. Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. Ensrud KE, Blackwell TL, Ancoli-Israel S, Redline S, Yaffe K, Diem S, Claman D, Stone KL;
The National Institute of Mental Health (NIMH), part of the National Institutes of Health, is funding 5 new research projects that will shed light on antidepressant medications, notably SSRIs and their association with suicidal thoughts and actions
CNS Spectr. 2006 Nov;11(11):879-83. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series. Dell'osso B, Mundo E, Altamura AC. Obsessive-compulsive d
Antidepressant drugs could lower men's sperm count, the first investigation of their effect on male fertility has found. A case report on two patients taking the most common class of antidepressants, which includes the market leaders
To determine the association between use of selective serotonin reuptake inhibitors (SSRIs) and objective measures of sleep disturbances in older community-dwelling women, including women without evidence of depression.
Breast-cancer patients should be told in prescribing information for the drug tamoxifen that a certain genetic profile or specific antidepressants might raise their risk of a relapse, advisers to U.S. regulators said. The panel of
